EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens

Chul-Hyun Lim iD, Jung-Hwan Oh iD

Gut and Liver · 2024

DOI: 10.5009/gnl230453 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Gut and Liver, 2024. Verfasst von Chul-Hyun Lim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, …. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Clarithromycin, Anti-Bacterial Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research Institute of Medical Science, Eunpyeong St. Mary’s Hospital, the Catholic University of Korea, Il-Yang Pharm. Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriClarithromycinAnti-Bacterial AgentsDrug Therapy, CombinationDrug Resistance, BacterialDrug Administration ScheduleBismuthHumansMaleFemaleMiddle AgedProspective StudiesAdultTreatment OutcomeAgedProton Pump InhibitorsAmoxicillinPeptic UlcerMetronidazoleBreath Tests

Stichwörter der Autor:innen

BismuthBreath testsClarithromycinHelicobacter pyloriReal-time polymerase chain reaction

Substanzen

ClarithromycinAnti-Bacterial AgentsBismuthProton Pump InhibitorsAmoxicillinMetronidazole

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

ORCID-Profile: Chul-Hyun Lim, Jung-Hwan Oh

Förderung

  • Research Institute of Medical Science, Eunpyeong St. Mary’s Hospital, the Catholic University of Korea
  • Il-Yang Pharm. Co., Ltd.

Zitieren

APA

Lim, C. H., & Oh, J. H. (2024). Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens. Gut and Liver. https://doi.org/10.5009/gnl230453

Vancouver

Lim CH, Oh JH. Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens. Gut and Liver. 2024. doi:10.5009/gnl230453

BibTeX
@article{Lim2024,
  author = {Lim, Chul-Hyun and Oh, Jung-Hwan},
  title = {Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens},
  journal = {Gut and Liver},
  year = {2024},
  doi = {10.5009/gnl230453}
}
Kostenlos starten →